Multisite study shows drug offers relief for symptoms of myelofibrosis
People with a blood cancer — myelofibrosis — can benefit from a drug called ruxolitinib, according to a randomized, double-blind, placebo-controlled clinical trial that included patients and researchers from the Stanford University School of Medicine, MD Anderson Cancer Center, and the Mayo Clinic in Scottsdale, Ariz... Individuals with advanced forms of myelofibrosis develop worsening blood counts, spleen enlargement and other symptoms including fever, night sweats and pain in their bones and muscles... In the study, many patients who received the drug experienced a significant reduction in spleen volume and a lessening of symptoms.
Among the research institutions NCI funds across the United States, it currently designates 66 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.